The vaccination landscape undergoes significant regulatory and organizational upheavals. The U.S. CDC’s Advisory Committee on Immunization Practices (ACIP) experienced a complete membership overhaul led by HHS Secretary Robert F. Kennedy Jr., stirring concerns over scientific credibility and vaccine scheduling reviews. ACIP meetings have included plans to reassess childhood vaccines and explore cumulative schedule effects amid widespread pushback from pediatric and medical associations. Concurrently, the FDA continues investigating Sarepta’s Duchenne gene therapy Elevidys following two patient deaths, while also requiring updates to COVID-19 vaccine labels for myocarditis risks. These shifts spotlight tensions between regulatory bodies, scientific communities, and public health policies.